Squamous Cell Carcinoma
Investigators determined the impact of socioeconomic status on disease status at presentation and survival among patients with head and neck squamous cell carcinoma.
In contrast of available prospective data, most older patients with locoregionally advanced head and neck cancer are treated with definitive radiotherapy also receive systemic therapy.
The incidence of oropharyngeal squamous cell carcinoma is increasing among older patients residing in the United States, likely due to the increase in HPV-associated malignancies.
A radiotherapeutic bandage is being evaluated by researchers for efficacy against squamous cell carcinoma (SCC) in an animal model. Their results could confirm the viability of a new and improved strategy for the radiotherapeutic treatment of skin cancer in the clinic.
Researchers have gained greater insight into the genetic abnormalities that lead the development, progression, and metastasis of skin cancer.
Rates of positive serologyand rapid urease tests were not different for head and neck cancer patients and controls, according to researchers.
The relatively high incidence of mouth squamous cell cancer in nonsmokers without obvious causes has been noted in studies, with nonsmokers having a higher proportion of cancers occur on the edge of the tongue.
Improved survival in patients with a peripheral squamous cell carcinoma has been linked to low blood levels of squamous cell carcinoma antigen or absence of tumor invasion into the space between the lungs and chest wall or into blood vessels.
Patients with recurrent or metastatic squamous cell carcinoma of the head and neck may benefit from treatment with the investigational drug dacomitinib.
The investigational drug BGJ398 showed promising anticancer activity in patients with various types of cancer driven by FGFR genetic alterations.
Sentinel lymph node dissection in women with vulvar malignancies allowed gynecologic oncology surgeons to identify and remove just the sentinel nodes and follow the patients for complications and recurrence.
An international team of researchers identified two biomarkers that were good at predicting a patient's resistance to radiation therapy for squamous cell cancer of the head and neck.
Initial symptom presentation seems to differ for human papillomavirus (HPV)-positive versus HPV-negative patients with oropharyngeal squamous cell carcinoma, according to a study.
Patients with HPV-positive squamous cell carcinoma of the oropharynx had a longer time to development of distant metastasis after initial treatment, and had more metastatic sites in more atypical locations.
Increased incidence of of oropharyngeal squamous cell carcinoma (OPSCC) among patients younger than 45 years seen, and steady increase in proportion of grade III/IV tumors.
A biomarker, adenosine deaminase acting on RNA-1 (ADAR1), has been discovered, and it has the potential to improve the diagnosis, prognosis, and treatment of esophageal squamous cell carcinoma.
Genomic and epigenomic alterations in the PAX gene family are associated with racial disparity in head and neck squamous cell carcinoma (HNSCC) survival, according to a study.
A definitive trial has indicated that low-level laser therapy reduces the occurrence of canker sores and improves quality of life in patients with head and neck squamous cell carcinoma who are undergoing concurrent chemoradiotherapy.
The human papillomavirus (HPV) triples the risk of people developing yet another cancer, esophageal squamous cell carcinoma (ESCC), according to new research.
A histology-expression predictor has been developed for the most common types of lung cancer and can corroborate the findings of pathologists.
A new function of the IB protein has been identified that is key in the development of squamous-cell carcinoma, a type of skin cancer. The study provides a new tool for the diagnosis of the disease. In the future, this research will enable the identification of novel therapeutic targets to treat this type of cancer.
The variety of genetic mutations (heterogeneity) of cells within a tumor appears to signal worse clinical outcomes in persons with HNSCC, a recent study demonstrated.
Adding erlotinib did not increase treatment toxicity in squamous cell carcinoma of the head and neck, but it also did not improve survival.
HNSCC is the seventh most common form of cancer in the United States. However, other than an association with HPV, no validated molecular profile of the disease has been established. By analyzing data from DNA microarrays, a study has confirmed the presence of four molecular classes of the disease.
Denosumab improved overall survival in persons with lung cancer and bone metastases more effectively than did zoledronic acid.
Two drugs under FDA evaluation slowed treatment resistance in persons with metastatic malignant melanoma positive for the BRAF protein.
Human papillomavirus (HPV) positivity alone is a poor biomarker for HPV-driven head and neck cancers, according to two recent studies.
Combo linked to less squamous cell carcinoma, higher response rates for BRAF V600 disease.
Drugs that inhibit mammalian target of rapamycin (mTOR) stopped radiation-induced damage in mice by protecting cells crucial to tissue repair.
New research shows that poor parental relationships can have a lasting impact on cancer risk.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|